cancer/testis antigen family 45 member A10Genealiases: []
Q-omics provides the consensus-scored CT45A10 profile across patient tissues and cancer cell-line models. CT45A10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CT45A10 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, CT45A10 RNA expression shows 7,471 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, HNSC, and TGCT as cancer lineages where CT45A10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CT45A10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CT45A10 survival associations across molecular data types. CT45A10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CT45A10 RNA expression–survival associations across cancer types. High CT45A10 expression shows unfavorable associations in COAD, KIRC, ACC, LIHC and DLBC, but favorable associations in OV. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CT45A10 RNA expression.
This table summarizes CT45A10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CT45A10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CT45A10 shows higher tumor expression in HNSC, BRCA and LUSC. The HNSC box plot shows higher CT45A10 RNA expression in tumor versus normal tissue (log2 FC = +1.205, t-test p = .001).
This table shows molecular features associated with CT45A10 in patient tissues and cancer cell lines. In patient samples, CT45A10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CT45A10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
